Achmea Investment Management BV has $32.12 million position in Johnson & Johnson (NYSE:JNJ)

Achmea Investment Management BV boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 8.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 219,746 shares of the company’s stock after purchasing an additional 16,340 shares during the quarter. Achmea Investment Management BV’s holdings in Johnson & Johnson were worth $32,118,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have added to or reduced their stakes in the stock. Meridian Financial Partners LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth $1,626,000. Summit Financial Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 26.3% in the first quarter. Summit Financial Wealth Advisors LLC now owns 5,392 shares of the company’s stock worth $853,000 after buying an additional 1,122 shares in the last quarter. Gilbert & Cook Inc. raised its position in Johnson & Johnson by 3.3% during the fourth quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after buying an additional 288 shares during the period. Franklin Parlapiano Turner & Welch LLC boosted its stake in Johnson & Johnson by 0.7% in the first quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the company’s stock valued at $7,464,000 after buying an additional 325 shares during the last quarter. Finally, Capital Asset Advisory Services LLC boosted its stake in shares of Johnson & Johnson by 8.8% in the first quarter. Capital Asset Advisory Services LLC now owns 26,539 shares of the company’s stock worth $4,044,000 after purchasing an additional 2,151 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s shares.

Johnson & Johnson stocks rose 0.5%

Shares of JNJ stock opened at $165.52 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44. The firm has a fifty day moving average of $159.55 and a 200 day moving average of $154.04. The company has a market cap of $398.45 billion, a price-to-earnings ratio of 10.32, a P/E/G ratio of 2.71 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue rose 4.3% year-over-year. In the same quarter last year, the company earned $2.80 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were paid a $1.24 dividend. This represents an annualized dividend of $4.96 and a yield of 3.00%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Analysts set new price targets

A number of equities analysts have issued reports on JNJ shares. Goldman Sachs Group reduced their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $160.00 to $150.00 in a research report on Tuesday. July 23. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 30th. TD Cowen cut their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $173.21.

Check out our latest review on JNJ

Insider trading at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC’s website. Company insiders hold 0.16% of the company’s shares.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Read more

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.